Synonyms: compound 17h [PMID: 38628803] | CRN-0489
Compound class:
Synthetic organic
Comment: CRN04894 is a small molecule melanocortin type 2 (MC2) receptor antagonist [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
CRN04894 is a clinical candidate for the treatment of congenital adrenal hyperplasia or Cushing's disease. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05804669 | A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome | Phase 1/Phase 2 Interventional | Crinetics Pharmaceuticals Inc. | ||
NCT05907291 | Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn) | Phase 2 Interventional | Crinetics Pharmaceuticals Inc. |